PROVOCHOLINE INHALATION SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

METHACHOLINE CHLORIDE; METHACHOLINE CHLORIDE; METHACHOLINE CHLORIDE; METHACHOLINE CHLORIDE; METHACHOLINE CHLORIDE

から入手可能:

METHAPHARM INC

ATCコード:

V04CX

INN（国際名）:

OTHER DIAGNOSTIC AGENTS

投薬量:

0.0625MG; 0.25MG; 1MG; 16MG; 4MG

医薬品形態:

SOLUTION

構図:

METHACHOLINE CHLORIDE 0.0625MG; METHACHOLINE CHLORIDE 0.25MG; METHACHOLINE CHLORIDE 1MG; METHACHOLINE CHLORIDE 16MG; METHACHOLINE CHLORIDE 4MG

投与経路:

INHALATION

パッケージ内のユニット:

100

処方タイプ:

Prescription

治療領域:

OTHER DIAGNOSTIC AGENTS

製品概要:

Active ingredient group (AIG) number: 0551578001; AHFS:

認証ステータス:

APPROVED

承認日:

2021-11-12

製品の特徴

_Product Monograph _
_ _
_PROVOCHOLINE (Methacholine Chloride) _
_Page 1 of 28_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PROVOCHOLINE
®
Methacholine Chloride (powder)
USP
100 mg, 160 mg, 320 mg, 1280 mg and 1600 mg
PR
PROVOCHOLINE
®
INHALATION SOLUTION (STERILE)
Methacholine Chloride Inhalation Solution
0 mg / mL, 0.0625 mg / mL, 0.25 mg / mL, 1 mg / mL, 4 mg / mL and 16
mg / mL
Cholinergic/Diagnostic Aid (Bronchial Airway Hyperresponsiveness)
Methapharm Inc.
81 Sinclair Boulevard
Brantford, Ontario
N3S 7X6
Date of Initial Authorization:

Date of Revision:
< Oct. 28, 2022>
Submission Control No: 249113
_ _
_Product Monograph _
_ _
_PROVOCHOLINE (Methacholine Chloride) _
_Page 2 of 28_
RECENT MAJOR LABEL CHANGES
1 Indications
[11/2021]
2 Contraindications
[11/2021]
3 Serious Warnings and Precautions Box
[11/2021]
4 Dosage and Administration
[11/2021]
7 Warnings and Precautions
[11/2021]
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES ................................................................................
2
TABLE OF CONTENTS
.......................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 4
1
INDICATIONS ...........................................................................................................
4
1.1
Pediatrics
............................................................................................................4
1.2
Geriatrics.............................................................................................................4
2
CONTRAINDICATIONS ...........................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX .............................................. 5
4
DOSAGE AND ADMINISTRATION ................................................................